Skip to content

Chronic Arterial Disease, Quality of Life and Mortality in Chronic Kidney Injury

Chronic Arterial Disease, Quality of Life and Mortality in Chronic Kidney Injury

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04223726
Acronym
CADKID
Enrollment
210
Registered
2020-01-10
Start date
2013-08-22
Completion date
2025-12-31
Last updated
2024-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Kidney Diseases

Keywords

chronic kidney disease, quality of life

Brief summary

CADKID-study is a prospective follow-up study assessing arterial disease, quality of life, mortality and their predictors in patients with severe chronic kidney disease.

Detailed description

Chronic kidney disease (CKD) is associated with increased risk of cardiovascular disease and mortality as well as impaired quality of life. Participants of this study all have severe CKD, defined as estimated glomerular filtration rate \< 30 ml/min per 1.73 m\^2. Stress ergometry, echocardiography, ultrasound assessment of arterial intima-media thickness, lateral lumbar radiograph, ECG, laboratory tests and quality of life assessment were performed at the baseline of the study and will be repeated during follow-up. Atrial fibrillation and other cardiac arrhythmias as well as pulse wave velocity measurements will be explored. Diet diaries are gathered and analysed. The aim of the study is to identify factors associated with cardiovascular disease, quality of life and mortality in this cohort.

Interventions

None listed

Sponsors

Turku University Hospital
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* estimated glomerular filtration rate \< 30 ml/min per 1.73 m\^2

Exclusion criteria

* age under 18 years * inability to give informed consent

Design outcomes

Primary

MeasureTime frame
Mortality5 years
Cardiovascular morbidity5 years

Secondary

MeasureTime frameDescription
Rate of hospitalizations2 years, 5 years
Abdominal aortic calcification (AAC) score2 years, 5 yearsScale 0-24, higher values indicate more calcification
Carotid intima-media thickness2 years, 5 years
Femoral intima-media thickness2 years, 5 years
Changes in quality of life2 years, 5 yearsKidney Disease Quality of Life Short Form (KDQOL-SF) instrument, consisting of 20 subscales (0-100), higher score indicating better quality of life
Maximal bicycle stress ergometry performance2 years, 5 yearsMean work load (watts) of the last 4 minutes of exercise, higher values indicating better performance
Left ventricular hypertrophy2 years, 5 yearsEchocardiography (Interventricular septum thickness, Posterior wall thickness, Left ventricular end-diastolic diameter, Left ventricular mass index)
Cardiac systolic function2 years, 5 yearsEchocardiography (Left ventricular ejection fraction, Left ventricular global longitudinal strain)
Cardiac diastolic function2 years, 5 yearsEchocardiography (ratio of the early to late ventricular filling velocities, ratio of transmitral Doppler early filling velocity to tissue Doppler early diastolic mitral annular velocity)
Flow-mediated dilatation of brachial artery2 years, 5 yearsDilatation at 60 seconds after the release of a cuff with pressure of 250 millimeters of mercury for 4.5 minutes, compared to at rest diameter
Number of participants with cardiac arrhythmias2 years, 5 years

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026